In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3418-3423

  Amsler, Karen M ^a   Davies, Todd A ^a   Shang, Wenchi ^a   Jacobs, Michael R ^b   Bush, Karen ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG ACTIVITY; DRUG POTENCY; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCUS;

EID: 50949091699     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00336-08     Document Type: Article

References (20)

1. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
2. Bradford, P. A., D. T. Weaver-Sands, and P. J. Petersen. 2005. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41(Suppl. 5):S315-S332.
3. Bush, K., M. Heep, M. J. Macielag, and G. J. Noel. 2007. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Exp. Opin. Investig. Drugs 16:419-429.
4. Citron, D. M., E. J. C. Goldstein, C. V. Merriam, B. A. Lipsky, and M. A Abramson. 2007. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin. Microbiol. 45:2819-2828.
5. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
6. DiNubile, M. J., and B. A. Lipsky. 2004. Complicated infections of skin and skin structures: when the infection is more than skin deep. J. Antimicrob. Chemother. 53(Suppl. 2):ii37-ii50.
7. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. P. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
8. Jauregui, L. E., S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, D. Krause, I. Satilovs, Z. Endzinas, J. Breaux, and W. O'Riordan. 2005. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41:1407-1415.
9. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
10. Lee, S. Y., J. L. Kuti, and D. P. Nicolau. 2005. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. 6:283-295.
11. Lipsky, B. A., P. Giordano, S. Choudhri, and J. Song. 2007. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J. Antimicrob. Chemother. 60:370-376.
12. Lodise, T. P., Jr., R. Pypstra, J. B. Kahn, B. P. Murthy, H. C. Kimko, K. Bush, G. J. Noel, and G. L. Drusano. 2007. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob. Agents Chemother. 51:2378-2387.
13. Moet, G. J., R. N. Jones, D. J. Biedenbach, M. G. Stilwell, and T. R. Fritsche. 2007. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn. Microbiol. Infect. Dis. 57:7-13.
14. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard M11-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
15. Noel, G., K. Bush, P. Bagchi, J. Ianus, and R. Strauss. 2008. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46:647-655.
16. Noel, G. J., R. S. Strauss, K. Amsler, M. Heep, R. Pypstra, and J. S. Solomkin. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob. Agents Chemother. 52:37-44.
17. Shang, W., A. Queenan, T. A. Davies, B. Morrow, R. K. Flamm, and K. Bush. 2007. Defining ceftobiprole wild-type and resistant populations in Pseudomonas aeruginosa. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C1-104. American Society for Microbiology, Washington, DC.
18. Steenbergen, J. N., J. Alder, G. M. Thorne, and F. P. Tally. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J. Antimicrob. Chemother. 55:283-288.
19. Walsh, T. R., A. Bolmström, A. Qwärnström, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
20. Weigelt, J., K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch, and C. S. G. Linezolid. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49:2260-2266.